• Home
  • PhD Medical Physics

PhD Medical Physics

PhD Medical physics

Overview

The PhD program in Medical Physics emphasizes advanced research at the interface of physics and healthcare. Major focus areas include medical imaging, radiotherapy optimization, dosimetry and quality assurance, radiation safety, AI and ML based applications. Scholars undertake interdisciplinary research aimed at improving diagnostic accuracy, treatment effectiveness and patient safety supported by expert supervision and modern research facilities. Current research areas include patient dose verification in radiotherapy, image processing techniques, extracorporeal irradiation, Monte Carlo simulation and experimental dosimetry.

Fee

Ph.D. Medical Physics Fee 2026

Programmes Duration (YR) Fee Payable I Year Fee II Year Onwards
Ph.D. Medical Physics 3 Yearly 162000 110000

Up to 100% Merit Scholarship

for outstanding students scoring above 90%.

Merit-Based Support

75% or 50% fee scholarships available for achievers with 80% and 70%+.

Merit-cum-Means Scholarship

50% tuition fee support for students with family income < ₹5 Lakh (min. 70% marks).

Special Scholarship

for Transgender, Differently-abled, and Wards of Non-Commissioned Officers (Up to 100% in UG / 50% in PG).

Free-ship for Orphans

one full free seat for the entire duration of the program.

Legacy & Support Benefits

Fee concession for SRHU staff wards & alumni continuing higher studies at SRHU.

SRHU University

Your Future Begins Here

Apply Now
   Admissions Form         

Admission Open For 2025

×
International Endowed Chair Professor

Prof Rakesh Kumar

Prof Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to vaddressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.